Stockscreener 앱 받기
2.03
0.00%
0.00
시간 외 거래:
2.05
0.02
+0.99%
전일 마감가:
$2.03
열려 있는:
$2.05
하루 거래량:
853.32K
Relative Volume:
0.47
시가총액:
$196.74M
수익:
$20.76M
순이익/손실:
$-132.49M
주가수익비율:
-0.7603
EPS:
-2.67
순현금흐름:
$-108.55M
1주 성능:
+3.57%
1개월 성능:
-23.97%
6개월 성능:
+37.16%
1년 성능:
-50.37%
1일 변동 폭
$2.015
$2.08
1주일 범위
$1.87
$2.185
52주 변동 폭
$1.085
$4.22
C 4 Therapeutics Inc Stock (CCCC) Company Profile
명칭
C 4 Therapeutics Inc
전화
(617) 231-0700
주소
490 ARSENAL WAY, WATERTOWN
CCCC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CCCC
C 4 Therapeutics Inc
|
2.03 | 196.74M | 20.76M | -132.49M | -108.55M | -2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
C 4 Therapeutics Inc Stock (CCCC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-02 | 개시 | TD Cowen | Buy |
| 2025-09-17 | 개시 | Barclays | Overweight |
| 2025-09-15 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2024-12-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-11-18 | 개시 | Stephens | Equal-Weight |
| 2024-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-12-13 | 업그레이드 | Stifel | Hold → Buy |
| 2023-02-24 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2023-02-24 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-10-11 | 개시 | Morgan Stanley | Underweight |
| 2022-04-28 | 개시 | Credit Suisse | Underperform |
| 2022-04-11 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-10 | 개시 | JP Morgan | Overweight |
| 2022-02-11 | 재개 | BMO Capital Markets | Outperform |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-11-23 | 개시 | BofA Securities | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Mkt Perform |
| 2021-09-30 | 개시 | Stifel | Hold |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-03-31 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-10-27 | 개시 | BMO Capital Markets | Outperform |
| 2020-10-27 | 개시 | Jefferies | Buy |
모두보기
C 4 Therapeutics Inc 주식(CCCC)의 최신 뉴스
Brookline Capital Management Estimates C4 Therapeutics FY2030 Earnings - MarketBeat
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fate Therapeutics reports new employee inducement awards under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Karyopharm Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 31, 2025 - BioSpace
Sarepta Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Is C4 Therapeutics (CCCC) one of the best biotech penny stocks to buy according to analysts? - MSN
Is C4 Therapeutics (CCCC) One of the Best Biotech Penny Stocks to Buy According to Analysts? - Insider Monkey
Abeona Therapeutics® announces new employee inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Caledonian Record
C4 Therapeutics, Inc. (NASDAQ:CCCC) Sees Significant Growth in Short Interest - MarketBeat
With 43% stake, C4 Therapeutics, Inc. (NASDAQ:CCCC) seems to have captured institutional investors' interest - Yahoo Finance
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Can C4 Therapeutics Inc. stock resist sector downturnsMarket Sentiment Report & Analysts Are Raving About These Shares - bollywoodhelpline.com
Is C4 Therapeutics Inc. stock in correction or buying zoneWeekly Profit Recap & Fast Moving Trade Plans - bolumsonucanavari.com
How C4 Therapeutics Inc. stock performs in weak economyWall Street Watch & Fast Exit and Entry Strategy Plans - Улправда
Energy Moves: How C4 Therapeutics Inc stock compares to growth peersWeekly Profit Analysis & Real-Time Stock Entry Alerts - moha.gov.vn
Can C4 Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Big Picture & Real-Time Buy Zone Alerts - Улправда
EV Market: Will C4 Therapeutics Inc. stock remain a Wall Street favoriteWeekly Investment Summary & Weekly Stock Breakout Alerts - Улправда
Exit Recap: Why C4 Therapeutics Inc. stock remains a top recommendationJuly 2025 Pullbacks & Real-Time Buy Zone Alerts - Улправда
Will C4 Therapeutics Inc. stock attract more institutional investors2025 Sector Review & Technical Pattern Based Signals - DonanımHaber
Layoff Watch: How C4 Therapeutics Inc. stock performs in weak economy2025 Trading Volume Trends & Safe Capital Investment Plans - Улправда
Will C4 Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Market Mood & Risk Controlled Stock Alerts - Улправда
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
How C4 Therapeutics Inc. stock performs during Fed tightening cycles2025 Risk Factors & Expert Approved Momentum Trade Ideas - Улправда
Why C4 Therapeutics Inc. stock remains a top recommendationDip Buying & Weekly High Return Stock Forecasts - Улправда
Barclays Maintains C4 Therapeutics (CCCC) Overweight Recommendation - Nasdaq
Barclays Lowers Price Target for C4 Therapeutics (CCCC) Despite Maintaining Overweight Rating | CCCC Stock News - GuruFocus
C4 Therapeutics Target of Unusually High Options Trading (NASDAQ:CCCC) - MarketBeat
Insufficient Growth At C4 Therapeutics, Inc. (NASDAQ:CCCC) Hampers Share Price - simplywall.st
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - PharmiWeb.com
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 11, 2025 - BioSpace
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Travere Therapeutics (NASDAQ: TVTX) issues 20,300 new-hire RSUs vesting over four years - Stock Titan
BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
What analysts say about C4 Therapeutics Inc stockEx-Dividend Date Alerts & Budget Friendly Trading Alerts - earlytimes.in
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
C 4 Therapeutics Inc (CCCC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.52%
0.07%
자본화:
|
볼륨(24시간):